A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-15-2014
Volume 2014 eBook
Issue 1

A study investigated the influence and correlation of critical process parameters for the optimization of in-process curing.

Previous studies with EUDRAGIT NM 30 D showed that storage stability can be achieved with in-process curing at specific conditions. The aim of this study was to identify and investigate the influence and correlation of critical process parameters for the optimization of in-process curing.

Download

Pharmaceutical Technology’s 2014 Solid Dosage and Excipients eBook

.

 

 

 

 

 

 

 

Articles in this issue
PTe0414_Colorcon.jpg
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
PTe0414_controlled.jpg
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
pte0414_hausnervideo.jpg
Continuous Manufacturing for Solid-Dosage Drug Production
PTe0414_Hovione.jpg
A Practical Guide to Hot-Melt Extrusion Scale-Up for Pharmaceutical Applications
PTe0414_ModWave.jpg
Using Modular Systems in Solid-Dosage Manufacturing
pte0414_Martinvideo.jpg
Advances in Hot-Melt Extrusion Manufacturing
PTe0414_Bohle.jpg
Obtaining User-Defined Particle Size Distribution Using Dry Granulation
PTe0414_evonik.jpg
A Quality-by-Design Approach to Optimize In-Process Curing of EUDRAGIT NM 30 D
PTe0414Generic.jpg
Selection of Excipients in Generic Formulations
Recent Videos
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

PTC Therapeutics Gains FDA Approval for AADC Deficiency Gene Therapy

Feliza Mirasol
November 19th 2024
Article

FDA's approval of eladocagene exuparvovec-tneq (Kebilidi) makes that product the first FDA-approved gene therapy for treating AADC deficiency.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Newly Opened Innovation Center in New Jersey Gives Avantor Advantage in Solving Life Sciences Challenges

Feliza Mirasol
November 15th 2024
Article

Avantor's newly launched expanded Innovation Center in Bridgewater, NJ, is designed for integrated workflows and features purpose-built collaboration spaces.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

MD Anderson Launches Cell Therapy Institute

Susan Haigney
November 11th 2024
Article

The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer

Feliza Mirasol
November 8th 2024
Article

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months.